PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
-1.92%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.61B
AUM Growth
+$2.61B
(-8%)
Cap. Flow
-$35.8M
Cap. Flow
% of AUM
-1.37%
Top 10 Holdings %
Top 10 Hldgs %
64.57%
Holding
44
New
10
Increased
10
Reduced
11
Closed
9
Top Buys
| 1 |
Merus
MRUS
|
$120M |
| 2 |
Revolution Medicines
RVMD
|
$91M |
| 3 |
Janux Therapeutics
JANX
|
$65.5M |
| 4 |
Cogent Biosciences
COGT
|
$30.6M |
| 5 |
Nuvalent
NUVL
|
$29.9M |
Top Sells
| 1 |
Immunocore
IMCR
|
$116M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$84.1M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$80.8M |
| 4 |
Vaxcyte
PCVX
|
$46.3M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
$41M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nuvalent
NUVL
$5.52B
| $347M | 13.27% | 4,571,678 +393,848 | +9% | +$29.9M |
|
2
argenx
ARGX
$43.6B
| $231M | 8.86% | 538,139 -13,981 | -3% | -$6.01M |
|
3
Arcellx
ACLX
$3.85B
| $212M | 8.13% | 3,848,095 +30,000 | +0.8% | +$1.66M |
|
|
4
Revolution Medicines
RVMD
$7.1B
| $204M | 7.81% | 5,259,089 +2,344,114 | +80% | +$91M |
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $150M | 5.73% | 947,574 -130,772 | -12% | -$20.7M |
|
6
Disc Medicine
IRON
$2.07B
| $122M | 4.67% | 2,704,718 +314,816 | +13% | +$14.2M |
|
|
7
Merus
MRUS
$4.98B
| $120M | 4.57% | +2,019,814 | New | +$120M |
|
8
Crinetics Pharmaceuticals
CRNX
$2.92B
| $113M | 4.31% | 2,513,302 -611,447 | -20% | -$27.4M |
|
|
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $95.3M | 3.65% | 2,330,508 | – | – |
|
10
Kura Oncology
KURA
$686M
| $93.5M | 3.58% | 4,539,381 +1,403,994 | +45% | +$28.9M |
|
11
Ascendis Pharma
ASND
$11.8B
| $90.6M | 3.47% | 664,307 +156,355 | +31% | +$21.3M |
|
12
Olema Pharmaceuticals
OLMA
$375M
| $85.5M | 3.27% | 7,903,600 | – | – |
|
13
Xenon Pharmaceuticals
XENE
$2.98B
| $79.7M | 3.05% | 2,043,280 -441,594 | -18% | -$17.2M |
|
14
Tarsus Pharmaceuticals
TARS
$2.47B
| $66.2M | 2.53% | 2,435,416 -427,990 | -15% | -$11.6M |
|
|
15
Janux Therapeutics
JANX
$1.37B
| $65.5M | 2.51% | +1,564,452 | New | +$65.5M |
|
16
Arvinas
ARVN
$568M
| $64.9M | 2.48% | 2,438,149 -176,786 | -7% | -$4.71M |
|
17
Legend Biotech
LEGN
$6.41B
| $53.3M | 2.04% | 1,203,308 -778,698 | -39% | -$34.5M |
|
|
18
Vaxcyte
PCVX
$4B
| $47.4M | 1.81% | 627,202 -612,793 | -49% | -$46.3M |
|
19
Y-mAbs Therapeutics
YMAB
$388M
| $46.8M | 1.79% | 3,870,594 +1,636,984 | +73% | +$19.8M |
|
20
Edgewise Therapeutics
EWTX
$1.51B
| $41.9M | 1.6% | 2,325,449 -120,924 | -5% | -$2.18M |
|
21
Immatics
IMTX
$619M
| $39.8M | 1.52% | 3,421,965 +603,057 | +21% | +$7.01M |
|
22
Viridian Therapeutics
VRDN
$1.5B
| $37.7M | 1.44% | 2,896,349 -2,135,071 | -42% | -$27.8M |
|
23
Immunovant
IMVT
$2.56B
| $36M | 1.38% | 1,362,827 +563,773 | +71% | +$14.9M |
|
|
24
Cogent Biosciences
COGT
$1.69B
| $30.6M | 1.17% | +3,624,342 | New | +$30.6M |
|
25
BridgeBio Pharma
BBIO
$9.89B
| $27.6M | 1.06% | +1,089,492 | New | +$27.6M |
|